The Execution Problem: Alex Gray and Jacqueline Poot on Pharma Decision Intelligence.

Welcome to IDEA Collider. In this episode, host Dr. Alex Gray, Chief Medical and Innovation Officer at IDEA Pharma, is joined by colleague Jacqueline Poot, President of Strategic Consulting and Analytics, to discuss the intricacies of pharmaceutical portfolio strategy. They tackle the growing view that the pharmaceutical industry doesn't just have a science problem; it has an execution problem. Alex breaks down how human biases, such as confirmation bias and champion bias, can derail clinical development and lead to poor portfolio choices. They emphasize that stopping a failing project early is just as critical to an organization's overall success as advancing a good one. The episode explores successful decision-making frameworks from top-performing companies, analyzing how AstraZeneca's 5Rs framework reversed late-stage failures and examining structured matrices such as Roche's RAVE, Amgen's RAVE, and Pfizer's DICE. Alex also highlights Eli Lilly's highly successful Chorus unit and their use of AI to drive objective resource allocation. Tune in to hear why relying solely on standard Probability of Technical Success (PTS) models or Risk-Adjusted NPV is flawed, how operational issues drive numerous Phase 3 failures, and the incremental but powerful role machine learning will play in the next generation of drug development. Episode Timestamps: 00:00:00 - Introduction: Jacqueline Poot and Dr. Alex Gray on maximizing scientific opportunity, managing risk, and long-term value. 00:02:09 - The Execution Problem: Why pharma struggles with evaluating multidisciplinary risks across clinical, commercial, and access domains. 00:11:10 - Combating Bias: Understanding champion bias, confirmation bias, and the danger of keeping projects alive purely on "wishful thinking". 00:16:13 - The Flaws of NPV: Why separating risk and reward provides a clearer picture of portfolio value than combined metrics. 00:22:09 - The Eli Lilly Story: Moving from the business of hope to the business of evidence, and the power of empowering the Chorus unit. 00:28:43 - The AstraZeneca 5Rs Framework: How focusing on the right target, patient, and commercial potential turned around the company's late-stage failure rate. 00:34:26 - RAVE and DICE: Exploring the structured, objective decision matrices of Roche, Amgen, and Pfizer. 00:46:49 - Probability of Technical Success (PTS): Why operational factors drive trial failures and why standard PTS simulations are imperfect. 00:58:50 - The Next Generation of Pharma Portfolios: Key takeaways on building cross-functional decision intelligence and portfolio agility. YouTube Tags: IDEA Collider, Alex Gray, Jacqueline Poot, IDEA Pharma, Pharma Portfolio Strategy, Decision Intelligence, Biotech Execution, Clinical Development Risks, AstraZeneca 5Rs, Eli Lilly Chorus, Pharma AI, Pfizer DICE, Roche RAVE, Probability of Technical Success, Drug Development, Confirmation Bias in Pharma, Biopharma Innovation, Operational Trial Failures.